US Bancorp’s Jasper Therapeutics JSPR Stock Holding History

US Bancorp’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$438	–	4268
2026 Q1	$438	Hold	500	–	–	﹤0.01%	4016
2025 Q4	$915	Hold	500	–	–	﹤0.01%	3868
2025 Q3	$1.19K	Hold	500	–	–	﹤0.01%	3816
2025 Q2	$2.77K	Hold	500	–	–	﹤0.01%	3800
2025 Q1	$2.15K	Sell	500 -11	-2%	-$73	﹤0.01%	3863
2024 Q4	$10.9K	Sell	511 -1	-0.2%	-$21	﹤0.01%	3377
2024 Q3	$9.63K	Buy	+512	New	+$10.2K	﹤0.01%	3379

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's JSPR Position: Q2 2026 in Review

US Bancorp sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 500 shares — an estimated $438 sold.

US Bancorp first reported a position in JSPR in Q3 2024 and held it in 7 quarters. The position peaked at $10.9K in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

US Bancorp reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 500 Jasper Therapeutics shares in Q2 2026, an estimated $438.
US Bancorp first reported a position in Jasper Therapeutics in Q3 2024 and held it in 7 quarters.
US Bancorp's Jasper Therapeutics position peaked at $10.9K in Q4 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.